• Nektar Therapeutics recently completed an upsized follow-on equity offering of about US$400.00 million in common stock and pre-funded warrants to help fund research, clinical development, and manufacturing for its pipeline.
• This capital raise closely followed positive 36-week maintenance data from the Phase 2b REZOLVE-AD trial of rezpegaldesleukin in moderate-to-severe atopic dermatitis, which showed durable disease control with both monthly and quarterly dosing and a consistent safety profile.
• We’ll now examine how these Phase 2b maintenance results for rezpegaldesleukin could reshape Nektar’s investment narrative around its lead asset.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Nektar Therapeutics Investment Narrative Recap

To own Nektar today, you have to believe rezpegaldesleukin can progress from promising Phase 2b data in atopic dermatitis into a viable late-stage program, while the company manages ongoing losses and dilution risk. The new US$400.0 million equity raise directly affects the near-term picture by extending the cash runway ahead of the planned Phase 3 start in 2026, but it also reinforces shareholder dilution as a key risk in the absence of commercial revenue.

The most relevant recent announcement for this catalyst is the 36 week REZOLVE AD maintenance readout, which showed durable disease control and a consistent safety profile across both monthly and quarterly dosing. This dataset underpins management’s plan to move rezpegaldesleukin into Phase 3 and helps explain why Nektar chose now to secure additional capital, potentially de-risking funding for upcoming trials while investors reassess execution and competitive risks.

Yet while the new data are encouraging, investors should still be aware of the risk that prolonged unprofitable operations and continued share issuance could...

Nektar Therapeutics’ narrative projects $40.9 million revenue and $9.5 million earnings by 2028.

Uncover how Nektar Therapeutics' forecasts yield a $114.43 fair value, a 72% upside to its current price.

Exploring Other Perspectives

Before this update, the most optimistic analysts were already assuming around US$55.3 million of revenue and US$12.8 million of earnings by 2028, which is far more upbeat than consensus. Against the fresh REZOLVE AD data and another large capital raise, you now have to decide whether that bullish view on faster de risking of the Treg platform still feels realistic or if the dependency on a few assets and ongoing cash burn makes it too aggressive.

Explore 4 other fair value estimates on Nektar Therapeutics - why the stock might be worth less than half the current price!

Build Your Own Nektar Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Nektar Therapeutics research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.
• Our free Nektar Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nektar Therapeutics' overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.